Core Scientific stock downgraded by JMP after CoreWeave acquisition news

Core Scientific (CORZ) is being acquired by CoreWeave in an all-stock deal valued at approximately $9 billion, or $20.40 per share, with CORZ shareholders receiving 10% of the combined entity upon the expected Q4 2025 close. Despite the premium, CORZ shares declined over 15% last week, reflecting investor disappointment over the all-stock structure and leading to downgrades from JMP Securities (to Market Perform) and BTIG (to Neutral), citing limited upside and balanced risk/reward. This acquisition is strategically significant for CoreWeave, aiming to eliminate over $10 billion in future lease overhead and significantly expand its data center capabilities for AI and high-performance computing workloads.

Analysis

Core Scientific Inc. (CORZ) has entered into an all-stock acquisition agreement with CoreWeave, valued at $20.40 per share, or approximately $9 billion in total. Despite this premium, CORZ stock reacted negatively, declining 15.64% over the past week to $12.51, reflecting investor disappointment with the deal's all-stock structure rather than a cash component. This sentiment led to downgrades from JMP Securities to Market Perform and BTIG to Neutral, with analysts citing a now-balanced risk/reward profile and limited further upside, especially given the low probability of a competing bid. The significant gap between the current trading price and the deal value highlights market skepticism and the long timeline, with the transaction not expected to close until Q4 2025, pending regulatory and shareholder approvals. For the acquirer, CoreWeave, the merger is strategically compelling as it aims to internalize data center capacity for AI workloads, which is projected to eliminate over $10 billion in future lease overhead and provide access to more favorable capital costs.

Key Decisions for Investors

• Investors should view Core Scientific primarily as a merger arbitrage opportunity, but must weigh the significant discount of its $12.51 price to the $20.40 deal value against the long closing timeline of Q4 2025 and the risks associated with an all-stock transaction.
• Given the downgrades and consensus view that a competing bid is unlikely, further near-term appreciation may be limited, making it prudent to monitor for any deal-related risks that could erode the current share price.
• Long-term investors bullish on the AI infrastructure sector might consider holding their position through the merger to gain ownership in the combined, more vertically integrated CoreWeave entity, despite the market's current disapproval of the deal terms.